Genmab — Share Issue/Capital Change 2018

Feb 28, 2018

Company Announcement

Copenhagen, Denmark; February 28, 2018 – Genmab A/S (Nasdaq Copenhagen: GEN)
will increase its share capital by 65,419 shares as a consequence of the
exercise of employee warrants.

The increase is effected without any preemption rights for the existing
shareholders of the company or others. The shares are subscribed in cash at the
following price per share of nominally DKK 1:

-- 220 shares at DKK 40.41,
-- 1,800 shares at DKK 68.65,
-- 3,625 shares at DKK 80.55,
-- 350 shares at DKK 210,
-- 250 shares at DKK 220.40,
-- 18,813 shares at DKK 225.90,
-- 200 shares at DKK 231.50,
-- 1,250 shares at DKK 234,
-- 1,250 shares at DKK 246,
-- 21,535 shares at DKK 254,
-- 6,850 shares at DKK 272,
-- 5,188 shares at DKK 337.40,
-- 88 shares at DKK 466.20, and
-- 4,000 shares at DKK 939.50.

Proceeds to the company are approximately DKK 18.3 million. The increase
corresponds to approx. 0.11% of the company's share capital.

The new shares are ordinary shares without any special rights and are freely
transferable negotiable instruments. The new shares give rights to dividends
and other rights in relation to the company as of subscription, i.e. inter alia
full rights to dividends for the financial year 2017. The new shares will be
listed on Nasdaq Copenhagen after registration with the Danish Business
Authority. The capital increase is expected to be finalized shortly.

Pursuant to section 32 of the Danish Capital Markets Act No 12 of January 8,
2018, it is hereby announced, that the total nominal value of Genmab A/S' share
capital after the capital increase is DKK 61,251,093, which is made up of
61,251,093 shares of a nominal value of DKK 1 each, corresponding to 61,251,093
votes.

About Genmab
Genmab is a publicly traded, international biotechnology company specializing
in the creation and development of differentiated antibody therapeutics for the
treatment of cancer. Founded in 1999, the company has two approved antibodies,
DARZALEX® (daratumumab) for the treatment of certain multiple myeloma
indications, and Arzerra® (ofatumumab) for the treatment of certain chronic
lymphocytic leukemia indications. Daratumumab is in clinical development for
additional multiple myeloma indications, other blood cancers, and solid tumors.
A subcutaneous formulation of ofatumumab is in development for relapsing
multiple sclerosis. Genmab also has a broad clinical and pre-clinical product
pipeline. Genmab's technology base consists of validated and proprietary next
generation antibody technologies - the DuoBody® platform for generation of
bispecific antibodies, and the HexaBody® platform which creates effector
function enhanced antibodies. The company intends to leverage these
technologies to create opportunities for full or co-ownership of future
products. Genmab has alliances with top tier pharmaceutical and biotechnology
companies. For more information visit www.genmab.com.

Contact:
Rachel Curtis Gravesen, Senior Vice President, Investor Relations &
Communications
T: +45 33 44 77 20; M: +45 25 12 62 60; E: rcg@genmab.com

This Company Announcement contains forward looking statements. The words
“believe”, “expect”, “anticipate”, “intend” and “plan” and similar expressions
identify forward looking statements. Actual results or performance may differ
materially from any future results or performance expressed or implied by such
statements. The important factors that could cause our actual results or
performance to differ materially include, among others, risks associated with
pre-clinical and clinical development of products, uncertainties related to the
outcome and conduct of clinical trials including unforeseen safety issues,
uncertainties related to product manufacturing, the lack of market acceptance
of our products, our inability to manage growth, the competitive environment in
relation to our business area and markets, our inability to attract and retain
suitably qualified personnel, the unenforceability or lack of protection of our
patents and proprietary rights, our relationships with affiliated entities,
changes and developments in technology which may render our products obsolete,
and other factors. For a further discussion of these risks, please refer to the
risk management sections in Genmab’s most recent financial reports, which are
available on www.genmab.com. Genmab does not undertake any obligation to update
or revise forward looking statements in this Company Announcement nor to
confirm such statements to reflect subsequent events or circumstances after the
date made or in relation to actual results, unless required by law.

Genmab A/S and/or its subsidiaries own the following trademarks: Genmab®; the
Y-shaped Genmab logo®; Genmab in combination with the Y-shaped Genmab logo®;
HuMax®; DuoBody®; DuoBody in combination with the DuoBody logo®; HexaBody®;
HexaBody in combination with the HexaBody logo®; and UniBody®. Arzerra® is a
trademark of Novartis AG or its affiliates. DARZALEX® is a trademark of Janssen
Pharmaceutica NV.

Company Announcement no. 06
CVR no. 2102 3884
LEI Code 529900MTJPDPE4MHJ122

Genmab A/S
Kalvebod Brygge 43
1560 Copenhagen V
Denmark